Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II camrelizumab plus platinum-based chemotherapy as first-line treatment for advanced NSCLC
ChiCTR2200065078Phase 2Not yet recruiting
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by General Hospital of Eastern Military Command. Primary endpoint: 6-month progression-free survival rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200065078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065078.